Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass

Biol Pharm Bull. 2015;38(11):1817-21. doi: 10.1248/bpb.b15-00334.

Abstract

Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h(-1), 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 µg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 µg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution.

Registration number: UMIN000007356.

MeSH terms

  • Aged
  • Ampicillin / administration & dosage
  • Ampicillin / blood
  • Ampicillin / pharmacokinetics
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Cardiopulmonary Bypass*
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Drug Administration Schedule
  • Female
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Injections, Intravenous
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Postoperative Complications / microbiology
  • Postoperative Complications / prevention & control*
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / prevention & control*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / growth & development
  • Sulbactam / administration & dosage
  • Sulbactam / blood
  • Sulbactam / pharmacokinetics
  • Sulbactam / therapeutic use

Substances

  • Anti-Bacterial Agents
  • sultamicillin
  • Ampicillin
  • Sulbactam

Associated data

  • JPRN/UMIN000007356